• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Unilife inks another pharma supply deal

Unilife inks another pharma supply deal

December 16, 2013 By Brad Perriello

Unilife inks another pharma supply deal

Unilife (NSDQ:UNIS) said it signed a supply deal with an unnamed "global pharmaceutical company" for its Ocu-ject eye drug delivery device.

"The identity of the global pharmaceutical company, 1 of the market leaders in ophthalmic therapies, as well as other terms of the agreement are not disclosed for commercial purposes and due to confidentiality requirements," according to a press release.

"In tune with our commitment to address unmet needs within the pharmaceutical industry, we have created a new, significant drug delivery device category. Ocu-ject represents a game-changing delivery technology for ocular therapies, which is a large, fast-growing segment of the pharmaceutical market. We are pleased to have signed our first agreement for the Ocu-ject device platform, which is being pursued by a number of pharmaceutical companies seeking to maximize the clinical and commercial potential of approved and pipeline drugs that are targeted to treat a number of eye disorders. We look forward to serving these customers to address unmet market needs for the accurate, precise delivery of drugs to the eye," chairman & CEO Alan Shortall said in prepared remarks.

The deal, which Unilife said will begin to generate revenue in January, is the latest in a string of supply deals that have buoyed its share price. The York, Pa.-based medtech company said earlier this month that it inked an exclusive deal with Novartis (NYSE:NVS) for a customized delivery device for 1 of the Swiss pharma giant’s novel investigational compounds "into a targeted organ in clinical trials."

Last month Unilife announced a 15-year, $40 million supply deal with British drug maker Hikma Pharmaceuticals (LON:HIK), hard on the heels of a similar pact for wearable injectors with Medimmune, AstraZeneca’s (NYSE:AZN) biologics arm. In September, Unilife signed a long-term contract to supply its Unifill Finesse anti-thrombotic-filled syringes exclusively to Sanofi (NYSE:SNY), a deal worth a minimum of $5 million and a maximum of $15 million in performance payments.

UNIS shares were trading at $4.41 apiece as of about 10:45 a.m. today, down 1.0%. The stock has gained 93.8% so far this year.

Filed Under: News Well, Pharmaceutical, Wall Street Beat Tagged With: Unilife Corp.

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy